Drug Profile
Research programme: anti-autoimmune disease therapeutic - Mitsubishi Tanabe Pharma/Nissan Chemical Industries
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation; Nissan Chemical Industries
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Autoimmune-disorders in Japan
- 21 Mar 2017 Mitsubishi Tanabe Pharma and Nissan Chemical Industries collaborate for the development of a therapeutic for the treatment of autoimmune disorders
- 21 Mar 2017 Early research in Autoimmune disorders in Japan (unspecified route)